Update on optimal use of omalizumab in management of asthma

References

• HolgateSTArshadHSRobertsGCHowarthPHThurnerPDaviesDEA new look at the pathogenesis of asthmaClin Sci2010118743945020025610
   PubMed Web of Science ®Google Scholar
• AndersonGPEndotyping asthma: new insights into key pathogenetic mechanisms in a complex, heterogeneous diseaseLancet200837296431107111918805339
   PubMed Web of Science ®Google Scholar
• AnandanCNurmatovUvan SchayckOCPSkeihAIs the prevalence of asthma declining? Systematic review of epidemiological studiesAllergy201065215216719912154
   PubMed Web of Science ®Google Scholar
• MasoliMFabianDHoltSBeasleyRThe global burden of asthma: executive summary of the GINA dissemination committee reportAllergy200459546947815080825
   PubMed Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL (GOAL) studyAm J Respir Crit Care Med2004170883684415256389
   PubMed Web of Science ®Google Scholar
• FantaCHDrug therapy: asthmaN Engl J Med2009360101002101419264689
   PubMed Web of Science ®Google Scholar
• BouletLPInfluence of comorbid conditions on asthmaEur Respir J200933489790619336592
   PubMed Web of Science ®Google Scholar
• DolanCMFraherKEBleeckerERDesign of baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthmaAnn Allergy Asthma Immunol2004921323914756462
   PubMed Web of Science ®Google Scholar
• GalliSJTsaiMPiliponskyAMThe development of allergic inflammationNature2008454720344545418650915
   PubMed Web of Science ®Google Scholar
• GouldHJSuttonBJIgE in allergy and asthma todayNat Rev Immunol20088320521718301424
   PubMed Web of Science ®Google Scholar
• PelaiaGVatrellaACalabreseCMazzarellaGMarsicoSANew perspectives in asthma treatmentAllergy200055Suppl 61606610919510
   PubMed Web of Science ®Google Scholar
• TarantiniFBaiardiniIPassalacquaGBraidoFCanonicaGWAsthma treatment: ‘Magic bullets which seek their own targets’Allergy200762660561017508963
   PubMed Web of Science ®Google Scholar
• HolgateSTPolosaRTreatment strategies for allergy and asthmaNat Rev Immunol20088321823018274559
   PubMed Web of Science ®Google Scholar
• HananiaNATargeting airway inflammation in asthma: current and future therapiesChest2008133498999818398119
   PubMed Web of Science ®Google Scholar
• ENFUMOSA (European Network For Understanding Mechanisms Of Severe Asthma) Study GroupThe ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthmaEur Respir J200322347047714516137
   PubMed Web of Science ®Google Scholar
• HaselkornTBorishLMillerDPWeissSTWongDAHigh prevalence of skin test positivity in severe or difficult-to-treat asthmaJ Asthma2006431074575217169826
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA)Global strategy for asthma management and prevention Available at: http://www.ginasthma.orgAccessed April 18, 2011
   Google Scholar
• European Public Assessment Report (Xolair) Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Xolair/emea-combined-h606en.pdfAccessed April 18, 2011
   Google Scholar
• PrestaLGLahrSJShieldsRLHumanization of an antibody directed against IgEJ Immunol19931515262326328360482
   PubMed Web of Science ®Google Scholar
• SpectorSOmalizumab efficacy in allergic diseasePanminerva Med200446214114815507883
   PubMed Web of Science ®Google Scholar
• ChangTWWuPCHsuCLHungAFAnti-IgE antibodies for the treatment of IgE-mediated allergic diseasesAdv Immunol2007936311917383539
   PubMed Web of Science ®Google Scholar
• HochhausGBrookmanLFoxHPharmacodynamics of omalizumab: implications for optimised dosing strategy and clinical efficacy in the treatment of allergic asthmaCurr Med Res Opin200319649149814594521
   PubMed Web of Science ®Google Scholar
• FoxJAHotalingTEStrubleCRuppelJBatesDJSchoenhoffMBTissue distribution and complex generation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeysJ Pharmacol Exp Ther19962792100010088930210
   PubMed Web of Science ®Google Scholar
• PrestaLShieldsRO’ConnellLThe binding site of a human immunoglobulin E for its high affinity receptorJ Biol Chem19942694226368263737929356
   PubMed Web of Science ®Google Scholar
• HolgateSCasaleTWenzelSBousquetJDenizYReisnerCThe anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJ Allergy Clin Immunol2005115345946515753888
   PubMed Web of Science ®Google Scholar
• MarcusPIncorporating anti-IgE (omalizumab) therapy in clinical practice: practice management implicationsChest2006129246647416478867
   PubMed Web of Science ®Google Scholar
• HendelesLSorknessCAAnti-immunoglobulin E therapy with omalizumab for asthmaAnn Pharmacother20074191397141017698897
   PubMed Web of Science ®Google Scholar
• D’AmatoGRole of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseasesEur J Pharmacol20065331–330230716464445
   PubMed Web of Science ®Google Scholar
• LanierBQCorrenJLumryWLiuJFowler-TaylorAGuptaNOmalizumab is effective in the long-term control of severe allergic asthmaAnn Allergy Asthma Immunol200391215415912952109
   PubMed Web of Science ®Google Scholar
• MillerCWTKrishnaswamyNJohnstonCKrishnaswamyGSevere asthma and the omalizumab optionClin Mol Allergy20086418489791
   PubMedGoogle Scholar
• BousquetJRabeKHumbertMPredicting and evaluating response to omalizumab in patients with severe allergic asthmaRespir Med200710171483149217339107
   PubMed Web of Science ®Google Scholar
• BousquetJSiergiejkoZSwiebockaEPersistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthmaAllergy201166567167821255035
   PubMed Web of Science ®Google Scholar
• FahyJVFlemingHEWongHHThe effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjectsAm J Respir Crit Care Med19971556182818349196082
   PubMed Web of Science ®Google Scholar
• BusseWCorrenJLanierBQOmalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of severe allergic asthmaJ Allergy Clin Immunol2001108218419011496232
   PubMed Web of Science ®Google Scholar
• SolérMMatzJTownleyRThe anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEur Respir J200118225426111529281
   PubMed Web of Science ®Google Scholar
• HolgateSTChuchalinAGHebertJEfficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthmaClin Exp Allergy200434463263815080818
   PubMed Web of Science ®Google Scholar
• VignolaAMHumbertMBousquetJEfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy200459770971715180757
   PubMed Web of Science ®Google Scholar
• AyresJGHigginsBChilversERAyreGBloggMFoxHEfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthmaAllergy200459770170815180756
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
   PubMed Web of Science ®Google Scholar
• PriceDThe use of omalizumab in asthmaPrim Care Respir J2008172627218425299
   PubMedGoogle Scholar
• PelaiaGRendaTRomeoPBuscetiMTMaselliROmalizumab in the treatment of severe asthma: efficacy and current problemsTher Adv Respir Res200826409421
   Google Scholar
• D’AmatoGPerticoneMBucchioniESalzilloAD’AmatoMLiccardiGTreating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An updateEur Ann Allergy Clin Immunol201042413514021114196
   PubMedGoogle Scholar
• RodrigoGJNeffenHCastro-RodriguezJAEfficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic reviewChest20111391283520688929
   PubMed Web of Science ®Google Scholar
• HananiaNAAlpanOHamilosDLOmalizumab in severe allegic asthma inadequately controlled with standard therapy: a randomized trialAnn Intern Med2011154957358221536936
   PubMed Web of Science ®Google Scholar
• BusseWWMorganWJGergenPJRandomized trial of omalizumab (anti-IgE) for asthma in inner-city childrenN Engl J Med2011364111005101521410369
   PubMed Web of Science ®Google Scholar
• MolimardMde BlayFDidierALe GrosVEffectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in FranceRespir Med20081021717617920257
   PubMed Web of Science ®Google Scholar
• KornSThielenASeyfriedSTaubeCKornmannOBuhlROmalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespir Med2009103111725173119515548
   PubMed Web of Science ®Google Scholar
• BrusselleGMichilsALouisR“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST studyRespir Med2009103111633164219619998
   PubMed Web of Science ®Google Scholar
• CazzolaMCamiciottoliGBonaviaMItalian real-life experience of omalizumabRespir Med2010104101410141620483574
   PubMed Web of Science ®Google Scholar
• MolimardMBuhlRNivenROmalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life dataRespir Med201010491381138520599369
   PubMed Web of Science ®Google Scholar
• SainiSSMacGlashanDWSterbinskySADown-regulation of human basophil IgE and FcɛRIα surface densities and mediator release by anti-IgE infusions is reversible in vitro and in vivoJ Immunol199916295624563910228046
   PubMed Web of Science ®Google Scholar
• CorrenJShapiroGReimannJAllergen skin tests and free IgE levels during reduction and cessation of omalizumab therapyJ Allergy Clin Immunol2008121250651118269927
   PubMed Web of Science ®Google Scholar
• NoppAJohanssonSGOAnkerstJPalmqvistMOmanHCD- sens and clinical changes during withdrawal of Xolair after 6 years of treatmentAllergy200762101175118117845588
   PubMed Web of Science ®Google Scholar
• BrownRTurkFDalePBousquetJCost-effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy200762214915317298423
   PubMed Web of Science ®Google Scholar
• DewildeSTurkFTambourMSandstromTThe economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to SwedenCurr Med Res Opin20062291765177616968580
   PubMed Web of Science ®Google Scholar
• BahadoriKQuonBSDoyle-WatersMMMarraCFitzgeraldJMA systematic review of economic evaluations of therapy in asthmaJ Asthma Allergy20103334221437038
   PubMedGoogle Scholar
• SullivanSDTurkFAn evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthmaAllergy200863667068418445184
   PubMed Web of Science ®Google Scholar
• CampbellJDSpackmanDESullivanSDThe costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspectiveAllergy20106591141114820148804
   PubMed Web of Science ®Google Scholar
• LedfordDKOmalizumab: overview of pharmacology and efficacy in asthmaExpert Opin Biol Ther20099793394319527111
   PubMed Web of Science ®Google Scholar
• HolgateSSmithNMassanariMJimenezPEffects of omalizumab on markers of inflammation in patients with allergic asthmaAllergy200964121728173619839977
   PubMed Web of Science ®Google Scholar
• BaiTRVonkJMPostmaDSBoezenHMSevere exacerbations predict excess lung function decline in asthmaEur Respir J200730345245617537763
   PubMed Web of Science ®Google Scholar
• DjukanovicRWilsonSJKraftMEffects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthmaAm J Respir Crit Care Med2004170658359315172898
   PubMed Web of Science ®Google Scholar
• PrietoLGutiérrezVColasCEffect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthmaInt Arch Allergy Immunol2006139212213116374021
   PubMed Web of Science ®Google Scholar
• SilkoffPERomeroFAGuptaNTownleyRGMilgromHExhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibodyPediatrics20041134e308e31215060258
   PubMed Web of Science ®Google Scholar
• NogaOHanfGKunkelGImmunological and clinical changes in allergic asthmatics following treatment with omalizumabInt Arch Allergy Immunol20031311465212759489
   PubMed Web of Science ®Google Scholar
• NogaOHanfGBrachmannIEffect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthmaJ Allergy Clin Immunol200611761493149916751018
   PubMed Web of Science ®Google Scholar
• MassanariMHolgateSTBusseWWJimenezPKianifardFZeldinREffect of omalizumab on peripheral blood eosinophilia in allergic asthmaRespir Med2010104218819619846286
   PubMed Web of Science ®Google Scholar
• HolgateSTDjukanovicRCasaleTBousquetJAnti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacyClin Exp Allergy200535440841615836747
   PubMed Web of Science ®Google Scholar
• CoxLPlatts-MillsTAEFinegoldISchwartzLBSimonsFERWallaceDVAmerican Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxisJ Allergy Clin Immunol200712061373137717996286
   PubMed Web of Science ®Google Scholar
• PriceKSHamiltonRGAnaphylactoid reactions in two patients after omalizumab administration after successful long-term therapyAllergy Asthma Proc200728331331917619560
   PubMed Web of Science ®Google Scholar
• CruzAALimaFSarinhoESafety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionsClin Exp Allergy200737219720717250692
   PubMed Web of Science ®Google Scholar
• WinchesterDEJacobAMurphyTOmalizumab for asthmaN Engl J Med2006355121281128216990394
   PubMed Web of Science ®Google Scholar
• PuéchalXRivereauPVinchonFChurg-Strauss syndrome associated with omalizumabEur J Intern Med200819536436618549941
   PubMed Web of Science ®Google Scholar
• BargagliEMadioniCOlivieriCPenzaFRottoliPChurg-Strauss vasculitis in a patient treated with omalizumabJ Asthma200845211511618350402
   PubMed Web of Science ®Google Scholar
• McDanelDLMullerBAThe linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?Ther Clin Risk Manag20051212514018360552
   PubMedGoogle Scholar
• US Food and Drug AdministrationEarly communication about an ongoing safety review of omalizumab (marketed as Xolair)June 162009
   Google Scholar
• CorrenJCasaleTBLanierBBuhlRHolgateSJimenezPSafety and tolerability of omalizumabClin Exp Allergy200939678879719302249
   PubMed Web of Science ®Google Scholar
• TanRACorrenJSafety of omalizumab in asthmaExpert Opin Drug Saf201110346347121401438
   PubMed Web of Science ®Google Scholar
• GirodetPOOzierABaraITunon de LaraJMMarthanRBergerPAirway remodeling in asthma: new mechanisms and potential for pharmacological interventionPharmacol Ther2011130332533721334378
   PubMed Web of Science ®Google Scholar
• MurdochJRLloydCMChronic inflammation in asthmaMutat Res20106901–2243919769993
   PubMed Web of Science ®Google Scholar
• HuangYCLeykoBFrierMEffects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cellsAnn Allergy Asthma Immunol200595544345116312167
   PubMed Web of Science ®Google Scholar
• ZietkowskiZSkiepkoRTomasiak-LozowskaMMBodzenta-LukaszykAAnti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthmaRespiration201080653454220588001
   PubMed Web of Science ®Google Scholar